Evolution of human papillomavirus carcinogenicity

Advances in Virus Research

Volumn 77, Issue C, 2010, Pages 41-62

  Van Doorslaer, Koenraad ^a   Burk, Robert D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN;

BOOK; CLASSIFICATION; FEMALE; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; METABOLISM; MOLECULAR EVOLUTION; PAPILLOMAVIRUS INFECTION; PATHOPHYSIOLOGY; PHYSIOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

EVOLUTION, MOLECULAR; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 77958198443     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385034-8.00002-8     Document Type: Book

References (98)

1. Antinore M.J., Birrer M.J., Patel D., Nader L., McCance D.J. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. Embo J. 1996, 15(8):1950-1960.
2. Arens M. Methods for subtyping and molecular comparison of human viral genomes. Clin. Microbiol. Rev. 1999, 12(4):612-626.
3. Arroyo M., Bagchi S., Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol. Cell. Biol. 1993, 13(10):6537-6546.
4. Band V., De Caprio J.A., Delmolino L., Kulesa V., Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J. Virol. 1991, 65(12):6671-6676.
5. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401(1):70-79.
6. Blakaj D.M., Fernandez-Fuentes N., Chen Z., Hegde R., Fiser A., Burk R.D., Brenowitz M. Evolutionary and biophysical relationships among the papillomavirus E2 proteins. Front. Biosci. 2009, 14:900-917.
7. Bodily J.M., Meyers C. Genetic analysis of the human papillomavirus type 31 differentiation-dependent late promoter. J. Virol. 2005, 79(6):3309-3321.
8. Bonne-Andrea C., Santucci S., Clertant P., Tillier F. Bovine papillomavirus E1 protein binds specifically DNA polymerase alpha but not replication protein A. J. Virol. 1995, 69(4):2341-2350.
9. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V. A review of human carcinogens-Part B: Biological agents. Lancet Oncol. 2010, 10(4):321-322.
10. Brehm A., Nielsen S.J., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. Embo J. 1999, 18(9):2449-2458.
11. Burchell A.N., Winer R.L., de Sanjose S., Franco E.L. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, 24(Suppl 3):52-61.
12. Burk R.D., Chen Z., Van Doorslaer K. Human papillomaviruses: Genetic basis of carcinogenicity. Public Health Genomics 2009, 12(5-6):281-290.
13. Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M., Phelps W.C., Nevins J.R. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl. Acad. Sci. USA 1992, 89(10):4549-4553.
14. Chen Z., Terai M., Fu L., Herrero R., DeSalle R., Burk R.D. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J. Virol. 2005, 79(11):7014-7023.
15. Chen Z., Schiffman M., Herrero R., DeSalle R., Burk R.D. Human papillomavirus (HPV) types 101 and 103 isolated from cervicovaginal cells lack an E6 open reading frame (ORF) and are related to gamma-papillomaviruses. Virology 2007, 360(2):447-453.
16. Cole S.T., Danos O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J. Mol. Biol. 1987, 193(4):599-608.
17. Conger K.L., Liu J.S., Kuo S.R., Chow L.T., Wang T.S. Human papillomavirus DNA replication. Interactions between the viral E1 protein and two subunits of human dna polymerase alpha/primase. J. Biol. Chem. 1999, 274(5):2696-2705.
18. Davies R., Hicks R., Crook T., Morris J., Vousden K. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J. Virol. 1993, 67(5):2521-2528.
19. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 32(1):17-27.
20. Dell'Oste V., Azzimonti B., De Andrea M., Mondini M., Zavattaro E., Leigheb G., Weissenborn S.J., Pfister H., Michael K.M., Waterboer T., Pawlita M., Amantea A., et al. High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J. Invest. Dermatol. 2009, 129(4):1026-1034.
21. Dobrosotskaya I., Guy R.K., James G.L. MAGI-1, a membrane-associated guanylate kinase with a unique arrangement of protein-protein interaction domains. J. Biol. Chem. 1997, 272(50):31589-31597.
22. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond) 2006, 110(5):525-541.
23. Doorbar J., Ely S., Sterling J., McLean C., Crawford L. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991, 352(6338):824-827.
24. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243(4893):934-937.
25. Einstein M.H., Leanza S., Chiu L.G., Schlecht N.F., Goldberg G.L., Steinberg B.M., Burk R.D. Genetic variants in TAP are associated with high-grade cervical neoplasia. Clin. Cancer Res. 2009, 15(3):1019-1023.
26. Virus taxonomy. The Eighth Report of the International Committee on Taxonomy of Viruses, Family Papillomaviridae 2005, 17. Elsevier. C.M. Fauquet, M.A. Mayo, J. Maniloff, U. Desselberger, L.A. Ball (Eds.).
27. Galloway D.A., Gewin L.C., Myers H., Luo W., Grandori C., Katzenellenbogen R.A., McDougall J.K. Regulation of telomerase by human papillomaviruses. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:209-215.
28. Gao Q., Srinivasan S., Boyer S.N., Wazer D.E., Band V. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Mol. Cell. Biol. 1999, 19(1):733-744.
29. Garcia-Vallve S., Alonso A., Bravo I.G. Papillomaviruses: Different genes have different histories. Trends Microbiol. 2005, 13(11):514-521.
30. Genovese N.J., Banerjee N.S., Broker T.R., Chow L.T. Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes. J. Virol. 2008, 82(10):4862-4873.
31. Grossman S.R., Laimins L.A. E6 protein of human papillomavirus type 18 binds zinc. Oncogene 1989, 4(9):1089-1093.
32. Han Y., Loo Y.M., Militello K.T., Melendy T. Interactions of the papovavirus DNA replication initiator proteins, bovine papillomavirus type 1 E1 and simian virus 40 large T antigen, with human replication protein A. J. Virol. 1999, 73(6):4899-4907.
33. Hasan U.A., Bates E., Takeshita F., Biliato A., Accardi R., Bouvard V., Mansour M., Vincent I., Gissmann L., Iftner T., Sideri M., Stubenrauch F., et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 2007, 178(5):3186-3197.
34. Helt A.M., Galloway D.A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 2003, 24(2):159-169.
35. Helt A.M., Funk J.O., Galloway D.A. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J. Virol. 2002, 76(20):10559-10568.
36. Herbst L.H., Lenz J., Van Doorslaer K., Chen Z., Stacy B.A., Wellehan J.F., Manire C.A., Burk R.D. Genomic characterization of two novel reptilian papillomaviruses, Chelonia mydas papillomavirus 1 and Caretta caretta papillomavirus 1. Virology 2009, 383(1):131-135.
37. Hiller T., Poppelreuther S., Stubenrauch F., Iftner T. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol. Biomarkers Prev. 2006, 15(7):1262-1267.
38. Hiller T., Stubenrauch F., Iftner T. Isolation and functional analysis of five HPVE6 variants with respect to p53 degradation. J. Med. Virol. 2008, 80(3):478-483.
39. Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., Basu J., Tachezy R., Lewis R., Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 1995, 87(18):1365-1371.
40. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998, 338(7):423-428.
41. Hon C.C., Lam T.Y., Drummond A., Rambaut A., Lee Y.F., Yip C.W., Zeng F., Lam P.Y., Ng P.T., Leung F.C. Phylogenetic analysis reveals a correlation between the expansion of very virulent infectious bursal disease virus and reassortment of its genome segment B. J. Virol. 2006, 80(17):8503-8509.
42. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., Harper J.W., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 2007, 81(18):9737-9747.
43. Jones D.L., Thompson D.A., Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 1997, 239(1):97-107.
44. Jones D.L., Thompson D.A., Suh-Burgmann E., Grace M., Munger K. Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway. Virology 1999, 258(2):406-414.
45. Kiyono T., Hiraiwa A., Fujita M., Hayashi Y., Akiyama T., Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 1997, 94(21):11612-11616.
46. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998, 396(6706):84-88.
47. Lechner M.S., Laimins L.A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 1994, 68(7):4262-4273.
48. Lee S.S., Weiss R.S., Javier R.T. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 1997, 94(13):6670-6675.
49. Liu X., Clements A., Zhao K., Marmorstein R. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 2006, 281(1):578-586.
50. Massimi P., Pim D., Banks L. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J. Gen. Virol. 1997, 78(Pt 10):2607-2613.
51. Masterson P.J., Stanley M.A., Lewis A.P., Romanos M.A. A C-terminal helicase domain of the human papillomavirus E1 protein binds E2 and the DNA polymerase alpha-primase p68 subunit. J. Virol. 1998, 72(9):7407-7419.
52. McIntyre M.C., Ruesch M.N., Laimins L.A. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 1996, 215(1):73-82.
53. McKaig R.G., Baric R.S., Olshan A.F. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck 1998, 20(3):250-265.
54. Morris J.D., Crook T., Bandara L.R., Davies R., LaThangue N.B., Vousden K.H. Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene 1993, 8(4):893-898.
55. Muench P., Hiller T., Probst S., Florea A.M., Stubenrauch F., Iftner T. Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. Virology 2009, 387(2):380-387.
56. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 1989, 63(10):4417-4421.
57. Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(S3):S1-S10.
58. Nakamura Y., Mashima Y., Kameyama K., Mukai M., Oguchi Y. Detection of human papillomavirus infection in squamous tumours of the conjunctiva and lacrimal sac by immunohistochemistry, in situ hybridisation, and polymerase chain reaction. Br. J. Ophthalmol. 1997, 81(4):308-313.
59. Narechania A., Chen Z., DeSalle R., Burk R.D. Phylogenetic incongruence among oncogenic genital alpha human papillomaviruses. J. Virol. 2005, 79(24):15503-15510.
60. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K., van der Linden H.C., Voorhorst F.J., Kenemans P., Meijer C.J. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 1999, 354(9172):20-25.
61. Nomine Y., Charbonnier S., Ristriani T., Stier G., Masson M., Cavusoglu N., Van D.A., Weiss E., Kieffer B., Trave G. Domain substructure of HPV E6 oncoprotein: Biophysical characterization of the E6 C-terminal DNA-binding domain. Biochemistry 2003, 42(17):4909-4917.
62. Nomine Y., Masson M., Charbonnier S., Zanier K., Ristriani T., Deryckere F., Sibler A.P., Desplancq D., Atkinson R.A., Weiss E., Orfanoudakis G., Kieffer B., et al. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol. Cell 2006, 21(5):665-678.
63. Oda H., Kumar S., Howley P.M. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc. Natl. Acad. Sci. USA 1999, 96(17):9557-9562.
64. Ohlenschlager O., Seiboth T., Zengerling H., Briese L., Marchanka A., Ramachandran R., Baum M., Korbas M., Meyer-Klaucke W., Durst M., Gorlach M. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene 2006, 25(44):5953-5959.
65. Orth G. Epidermodysplasia verruciformis: A model for understanding the oncogenicity of human papillomaviruses. Ciba Found. Symp. 1986, 120:157-174.
66. Rector A., Lemey P., Tachezy R., Mostmans S., Ghim S.J., Van D.K., Roelke M., Bush M., Montali R.J., Joslin J., Burk R.D., Jenson A.B., et al. Ancient papillomavirus-host co-speciation in Felidae. Genome Biol. 2007, 8(4):R57.
67. Richard C., Lanner C., Naryzhny S.N., Sherman L., Lee H., Lambert P.F., Zehbe I. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene 2010, 29(23):3435-3445.
68. Rodriguez A.C., Schiffman M., Herrero R., Hildesheim A., Bratti C., Sherman M.E., Solomon D., Guillen D., Alfaro M., Morales J., Hutchinson M., Katki H., Cheung L., Wacholder S., Burk R.D. Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. J. Natl. Cancer Inst. 2010, 102(5):315-324.
69. Rolfe M., Beer-Romero P., Glass S., Eckstein J., Berdo I., Theodoras A., Pagano M., Draetta G. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc. Natl. Acad. Sci. USA 1995, 92(8):3264-3268.
70. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63(6):1129-1136.
71. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75(3):495-505.
72. Schiffman M., Kjaer S.K. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monogr. 2003, 31:14-19.
73. Schiffman M., Herrero R., DeSalle R., Hildesheim A., Wacholder S., Rodriguez A.C., Bratti M.C., Sherman M.E., Morales J., Guillen D., Alfaro M., Hutchinson M., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337(1):76-84.
74. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., Duarte-Franco E., Rohan T.E., Ferenczy A., Villa L.L., Franco E.L. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. Jama 2001, 286(24):3106-3114.
75. Schwartz S. Regulation of human papillomavirus late gene expression. Ups. J. Med. Sci. 2000, 105(3):171-192.
76. Seret M.L., Diffels J.F., Goffeau A., Baret P.V. Combined phylogeny and neighborhood analysis of the evolution of the ABC transporters conferring multiple drug resistance in hemiascomycete yeasts. BMC Genomics 2009, 10:459.
77. Shimodaira H., Hasegawa M. Multiple comparisons of log-likelihoods with applications to phylogenetic inference. Mol. Biol. Evol. 1999, 16:3.
78. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int. J. Cancer 2007, 121(3):621-632.
79. Smith G.J., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., Ma S.K., Cheung C.L., Raghwani J., Bhatt S., Peiris J.S., Guan Y., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459(7250):1122-1125.
80. Spink K.M., Laimins L.A. Induction of the human papillomavirus type 31 late promoter requires differentiation but not DNA amplification. J. Virol. 2005, 79(8):4918-4926.
81. Stamatakis A., Ludwig T., Meier H. RAxML-III: A fast program for maximum likelihood-based inference of large phylogenetic trees. Bioinformatics 2005, 21(4):456-463.
82. Steger G., Pfister H. In vitro expressed HPV 8 E6 protein does not bind p53. Arch. Virol. 1992, 125(1-4):355-360.
83. Thomas M., Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 1999, 80(Pt 6):1513-1517.
84. Thomas M., Narayan N., Pim D., Tomaic V., Massimi P., Nagasaka K., Kranjec C., Gammoh N., Banks L. Human papillomaviruses, cervical cancer and cell polarity. Oncogene 2008, 27(55):7018-7030.
85. Tomaic V., Gardiol D., Massimi P., Ozbun M., Myers M., Banks L. Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators. Oncogene 2009, 28(1):1-8.
86. Tong X., Howley P.M. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc. Natl. Acad. Sci. USA 1997, 94(9):4412-4417.
87. Tong X., Salgia R., Li J.L., Griffin J.D., Howley P.M. The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J. Biol. Chem. 1997, 272(52):33373-33376.
88. Vambutas A., DeVoti J., Pinn W., Steinberg B.M., Bonagura V.R. Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin. Immunol. 2001, 101(1):94-99.
89. Van Doorslaer K., Rector A., Vos P., Van Ranst M. Genetic characterization of the Capra hircus papillomavirus: A novel close-to-root artiodactyl papillomavirus. Virus Res. 2006, 118(1-2):164-169.
90. Van Doorslaer K., Sidi A.O., Zanier K., Rybin V., Deryckere F., Rector A., Burk R.D., Lienau E.K., van Ranst M., Trave G. Identification of unusual E6 and E7 proteins within avian papillomaviruses: Cellular localization, biophysical characterization, and phylogenetic analysis. J. Virol. 2009, 83(17):8759-8770.
91. Veldman T., Horikawa I., Barrett J.C., Schlegel, R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J. Virol. 2001, 75(9):4467-4472.
92. Watts S.L., Ostrow R.S., Phelps W.C., Prince J.T., Faras A.J. Free cottontail rabbit papillomavirus DNA persists in warts and carcinomas of infected rabbits and in cells in culture transformed with virus or viral DNA. Virology 1983, 125(1):127-138.
93. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 2001, 248(4951):76-79.
94. Wodarz A., Nathke I. Cell polarity in development and cancer. Nat. Cell Biol. 2007, 9(9):1016-1024.
95. Yang L., Li R., Mohr I.J., Clark R., Botchan M.R. Activation of BPV-1 replication in vitro by the transcription factor E2. Nature 1991, 353(6345):628-632.
96. Zhao K.N., Sun X.Y., Frazer I.H., Zhou J. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 1998, 243(2):482-491.
97. Zhao K.N., Hengst K., Liu W.J., Liu Y.H., Liu X.S., McMillan N.A., Frazer I.H. BPV1 E2 protein enhances packaging of full-length plasmid DNA in BPV1 pseudovirions. Virology 2000, 272(2):382-393.
98. Zhou J., Liu W.J., Peng S.W., Sun X.Y., Frazer I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J. Virol. 1999, 73(6):4972-4982.